Loading this company
Moderna, Inc.
MRNAPrices in USD
TickerWorth ScoreF29/100
What we think
We do not publish a fair value for this company. The grade still applies.
Price
$218.01USD down −$18.49 (−7.82%)
Quoted · Prices are delayed.
This price comes from our backup market-data feed.
Why did it move today?
Nothing we can cite explains today’s move for this company.
We do not put a fair value on this one
Our cash-flow model doesn't produce a meaningful value for this business — its projected free cash flow is so far from supporting the current price that the result is effectively zero, which tells you about the limits of the model on a fast-growing or loss-making company, not about what the business is worth. Here is what we can show instead.
Is it a good business?
- Valuation0 out of 100
- Growth50 out of 100
- Financial health100 out of 100
- Past performance33 out of 100
Bull, base, bear
Our forward range over 12 months is part of Pro. See plans
The street
Analysts’ mean target
$123.61 across 18 analysts
The high and low of the analyst range is part of Pro. See plans
What does it do?
Moderna is a biotechnology company that develops messenger RNA medicines. Its products include vaccines for respiratory diseases (COVID-19, RSV, influenza), latent viral infections (cytomegalovirus, Epstein-Barr virus, HIV), and other conditions, as well as oncology therapeutics and rare disease treatments.
Key stats
52-week range$22.28–$242.29
- Open
- $234.90
- Day high
- $237.96
- Day low
- $209.00
- Previous close
- $236.50
- Volume
- 21,334,738 · 1.12× avg
- Average volume
- 19,101,471
- Market cap
- $87,037,419,520.00
- P/E (TTM)
- —
- Earnings per share
- −$7.98
- Beta
- 1.10
Prices are delayed. The feed does not say when these figures were taken.
What’s the latest?
- Changed leadership or its board
- Signed a material agreement
- Reported quarterly or annual results
- Changed leadership or its board
- Amended its charter or bylaws
- Reported quarterly or annual results
- Signed a material agreement
Top news
No recent headlines we can cite for this company.
Insider trades
The 90-day buying-and-selling read is part of Pro. See plans
- Hoge StephenOption exercise · $933,478.92
- Hoge StephenOpen-market sale ·
Not investment advice. TickerWorth Score is a model output.